Skip to main content
Book cover

Penile Cancer pp 135–148Cite as

New Systemic Approaches and Clinical Trials in Penile Cancer

  • 717 Accesses

Part of the Current Clinical Urology book series (CCU)

Abstract

The roots of medical therapy of penile cancer include conventional chemotherapy agents, and some early use of immunotherapy, namely interferon. While the development of further use of conventional chemotherapy continues to the present, including not just timing, combination, and route of administration variations, the use of newer agents in the targeted therapy and immunotherapy categories is seen across all oncologic therapeutics. Penile cancer is not different, with molecular analyses trying to tie into particular targets, such as epidermal growth factor receptor. Immune treatments both from the perspective of general immune modulations with checkpoint inhibitors, and also leveraging specific features of human papillomavirus (HPV), for HPV-associated squamous penile cancer are of interest as well.

Keywords

  • Cisplatin
  • Clinical trial
  • Targeted therapy
  • HPV

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4939-6679-0_10
  • Chapter length: 14 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   84.99
Price excludes VAT (USA)
  • ISBN: 978-1-4939-6679-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   109.99
Price excludes VAT (USA)
Hardcover Book
USD   109.99
Price excludes VAT (USA)
Learn about institutional subscriptions
Fig. 10.1

References

  1. Sklaroff RB, Yagoda A. Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinoma. Cancer. 1979;44(5):1563–5.

    CAS  CrossRef  PubMed  Google Scholar 

  2. Gagliano RG, Blumenstein BA, Crawford ED, Stephens RL, Coltman Jr CA, Costanzi JJ. cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol. 1989;141(1):66–7.

    CAS  PubMed  Google Scholar 

  3. Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer. 1990;65(3):433–8.

    CAS  CrossRef  PubMed  Google Scholar 

  4. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992;147(3):630–2.

    CAS  PubMed  Google Scholar 

  5. Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, D’Aniello C, Puglia L, Petremolo A, Ferro M, Marinelli A, Palmieri G, Sonpavde G, Mirone V, De Placido S. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int. 2012;110(11 Pt B):E661–6.

    Google Scholar 

  6. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Fitz K, Striegel A. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol. 1991;146(5):1284–7.

    CAS  PubMed  Google Scholar 

  7. Kattan J, Culine S, Droz JP, Fadel E, Court B, Perrin JL, Wibault P, Haie-Meder C. Penile cancer chemotherapy: twelve years’ experience at Institut Gustave-Roussy. Urology. 1993;42(5):559–62.

    CAS  CrossRef  PubMed  Google Scholar 

  8. Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999;161(6):1823–5.

    CAS  CrossRef  PubMed  Google Scholar 

  9. Di Lorenzo G, Cartenì G, Autorino R, Gonnella A, Perdonà S, Ferro M, Longo N, Rescigno P, Doria F, Faiella A, Altieri V, Palmieri G, Imbimbo C, Mirone V, De Placido S. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. Anticancer Drugs. 2009;20(4):277–80.

    CrossRef  PubMed  Google Scholar 

  10. Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol. 2007;177(4):1335–8.

    CrossRef  PubMed  Google Scholar 

  11. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851–7.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  12. Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, Elliott T, Thomson A, Burnett S, Cruickshank C, Carrington B, Waters R, Bahl A. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer. 2013;109(10):2554–9.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  13. Zhang S, Zhu Y, Ye D. Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. Oncotarget. 2015;6(31):32212–9.

    PubMed  PubMed Central  Google Scholar 

  14. Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD, EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008;19(7):1304–7.

    CAS  CrossRef  PubMed  Google Scholar 

  15. Power DG, Galvin DJ, Cuffe S, McVey GP, Mulholland PJ, Farrelly C, Delaney DW, O’Byrne KJ. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol. 2009;27(2):187–90.

    CAS  CrossRef  PubMed  Google Scholar 

  16. Houédé N, Dupuy L, Fléchon A, Beuzeboc P, Gravis G, Laguerre B, Théodore C, Culine S, Filleron T, Chevreau C. Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma. BJU Int. 2016;117(3):444–9.

    CrossRef  PubMed  Google Scholar 

  17. Roth AD, Berney CR, Rohner S, Allal AS, Morel P, Marti MC, Aapro MS, Alberto P. Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential. Br J Cancer. 2000;83(12):1637–42.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  18. Chen CH, Kang CH, Chiang PH. Intra-arterial infusion of chemotherapy in the treatment of penile cancer. Jpn J Clin Oncol. 2009;39(12):825–8.

    CrossRef  PubMed  Google Scholar 

  19. Huang XY, Kubota Y, Nakada T, Sasagawa I, Suzuki H, Ishigooka M. Intra-arterial infusion chemotherapy for penile carcinoma with deep inguinal lymph node metastasis. Urol Int. 1999;62(4):245–8.

    CAS  CrossRef  PubMed  Google Scholar 

  20. Liu JY, Li YH, Liu ZW, Zhang ZL, Ye YL, Yao K, Han H, Qin ZK, Zhou FJ. Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma. Chin J Cancer. 2013;32(11):619–23.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  21. Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int. 2006;98(6):1225–7.

    CAS  CrossRef  PubMed  Google Scholar 

  22. NCCN Penile cancer guideline. http://www.NCCN.org. Accessed 29 Feb 16.

  23. Nicolai N, Sangalli LM, Necchi A, Giannatempo P, Paganoni AM, Colecchia M, Piva L, Catanzaro MA, Biasoni D, Stagni S, Torelli T, Raggi D, Faré E, Pizzocaro G, Salvioni R. A combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings. Clin Genitourin Cancer. 2016;14(4):323–30.

    CrossRef  PubMed  Google Scholar 

  24. Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ, Spanish Head and Neck Cancer Cooperative Group (TTCC). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25(1):216–25.

    CAS  CrossRef  PubMed  Google Scholar 

  25. Qin H, Luo J, Zhu YP, Xie HL, Yang WQ, Lei WB. Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis. PLoS One. 2012;7(12):e51526.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  26. Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol. 2012;2:169.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  27. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498–509.

    CrossRef  PubMed  Google Scholar 

  28. Umayahara K, Takekuma M, Hirashima Y, Noda SE, Ohno T, Miyagi E, Hirahara F, Hirata E, Kondo E, Tabata T, Nagai Y, Aoki Y, Wakatsuki M, Takeuchi M, Toita T, Takeshima N, Takizawa K. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: the JACCRO GY-01 trial. Gynecol Oncol. 2016;140(2):253–8.

    CAS  CrossRef  PubMed  Google Scholar 

  29. Urban D, Corry J, Solomon B, Lim AM, Fua T, Coleman A, D’Costa I, Tiong A, Liu C, Peters LJ, Rischin D. Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head Neck. 2016;38 Suppl 1:E1117–21.

    CrossRef  PubMed  Google Scholar 

  30. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348(9034):1049–54.

    Google Scholar 

  31. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA, BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88.

    CAS  CrossRef  PubMed  Google Scholar 

  32. Mitropoulos D, Dimopoulos MA, Kiroudi-Voulgari A, Zervas A, Dimopoulos C, Logothetis CJ. Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinoma. J Urol. 1994;152(4):1124–6.

    CAS  PubMed  Google Scholar 

  33. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis. 2001;1:3.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  34. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  35. Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ, Gutkind JS, Kulkarni AB, Sun ZJ. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma. Oncotarget. 2015;6(39):42067–80.

    PubMed  PubMed Central  Google Scholar 

  36. Borradori L, Sutton B, Shayesteh P, Daniels GA. Rescue therapy with anti-programmed cell death protein 1 inhibitors (PD-1) of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in 5 cases. Br J Dermatol. 2016.

    Google Scholar 

  37. Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol. 2016;57:54–60.

    CAS  CrossRef  PubMed  Google Scholar 

  38. Carrega P, Loiacono F, Di Carlo E, Scaramuccia A, Mora M, Conte R, Benelli R, Spaggiari GM, Cantoni C, Campana S, Bonaccorsi I, Morandi B, Truini M, Mingari MC, Moretta L, Ferlazzo G. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun. 2015;6:8280.

    CAS  CrossRef  PubMed  Google Scholar 

  39. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep. 2012;2:765.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  40. Kim H, Kwon B, Sin JI. Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses. PLoS One. 2013;8(12):e83765.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  41. Sharma C, Khan MA, Mohan T, Shrinet J, Latha N, Singh N. A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer. Immunol Res. 2014;58(1):132–8.

    CAS  CrossRef  PubMed  Google Scholar 

  42. Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, Lee CW, Kim S, Woo JW, Park KS, Hwang YY, Park J, Lee IH, Lim KT, Lee KH, Jeong MS, Surh CD, Suh YS, Park JS, Sung YC. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  43. Scholten KB, Turksma AW, Ruizendaal JJ, van den Hende M, van der Burg SH, Heemskerk MH, Meijer CJ, Hooijberg E. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med. 2011;9:147.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  44. Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev. 2015;263(1):68–89.

    CAS  CrossRef  PubMed  Google Scholar 

  45. Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543–50.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  46. Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015;36(7):422–39.

    CAS  CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, USA

    Mayer Fishman M.D., Ph.D.

Authors
  1. Mayer Fishman M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mayer Fishman M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Genitourinary Oncology, Department of Tumor Biology, Moffitt Cancer Center, Tampa, Florida, USA

    Philippe E. Spiess

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this chapter

Cite this chapter

Fishman, M. (2017). New Systemic Approaches and Clinical Trials in Penile Cancer. In: Spiess, P. (eds) Penile Cancer. Current Clinical Urology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6679-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6679-0_10

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6677-6

  • Online ISBN: 978-1-4939-6679-0

  • eBook Packages: MedicineMedicine (R0)